15 October 2021 in Journal of Thrombosis and Haemostasis
Background Occlusive thrombi are not homogeneous in composition. The core of a thrombus is rich in activated platelets and fibrin while the outer shell contains resting platelets. This core is inaccessible to plasma proteins. We produced a fusion protein (targeted SERPIN – TaSER), consisting of a function-blocking VHH against glycoprotein Ibα and a thrombin-inhibiting serine protease inhibitor (SERPIN; α1-antitrypsin 355AIAR358) to interfere with platelet-driven thrombin formation. Aim To evaluate the antithrombotic properties of TaSER. Methods Besides TaSER, we generated three analogous control variants with either a wild-type antitrypsin subunit, a non-targeting control VHH, or their combination. We investigated TaSER and controls in protease activity assays, (platelet-dependent) thrombin generation assays and by western blotting. The effects of TaSER on platelet activation and von Willebrand Factor (VWF)-binding were studied by FACS, in agglutination studies and in ATP secretion experiments. We studied the influence of TaSER in whole blood 1) on platelet adhesion on VWF, 2) aggregate formation on collagen and 3) thrombus formation (after recalcification) on collagen and tissue-factor. Results TaSER binds platelets and inhibits thrombin activity on the platelet surface. It blocks VWF binding and disassembles platelet agglutinates. TaSER delays tissue factor-triggered thrombin generation and ATP secretion in platelet-rich plasma in a targeted manner. In flow studies, TaSER interferes with platelet adhesion and aggregate formation due to GPIbα blockade and limits thrombus formation due to targeted inhibition of platelet-dependent thrombin activity. Conclusion The synergy between the individual properties of TaSER makes it a highly effective antithrombotic agent with possible clinical implications.
17 June 2024 in Journal of Thrombosis and Haemostasis
Factor (F)XII triggers contact activation by binding to foreign surfaces, with the epidermal growth factor-like 1 (EGF-1) domain being the primary binding site. Blocking FXII surface-binding might hold therapeutic value to prevent medical device-induced thrombosis. To unravel and prevent EGF-1-mediated FXII surface-binding with a variable domain of heavy chain-only antibody (VHH). FXII variants with glutamine substitutions of 2 positively charged amino acid patches within the EGF-1 domain were created. Their role in FXII contact activation was assessed using kaolin pull-down experiments, amidolytic activity assays, and clotting assays. FXII EGF-1 domain-specific VHHs were raised to inhibit EGF-1-mediated FXII contact activation while preserving quiescence. Two unique, positively charged patches in the EGF-1 domain were identified (upstream, 73K74K76K78H81K82H; downstream, 87K113K). Neutralizing the charge of both patches led to a 99% reduction in FXII kaolin binding, subsequent decrease in autoactivation of 94%, and prolongation of clot formation in activated partial thromboplastin time assays from 36 (±2) to 223 (±13) seconds. Three FXII EGF-1-specific VHHs were developed that are capable of inhibiting kaolin binding and subsequent contact system activation in plasma. The most effective VHH "F2" binds the positively charged patches and thereby dose-dependently extends activated partial thromboplastin time clotting times from 29 (±2) to 43 (±3) seconds without disrupting FXII quiescence. The 2 unique, positively charged patches in FXII EGF-1 cooperatively mediate FXII surface-binding, making both patches crucial for contact activation. Targeting these with FXII EGF-1-specific VHHs can exclusively decrease FXII surface-binding and subsequent contact activation, while preserving zymogen quiescence. These patches thus have potential as druggable targets in preventing medical device-induced thrombosis.
30 October 2025 in Blood Vessels, Thrombosis & Hemostasis